Jason Hsu is Director at Immix Biopharma, Inc. (IMMX). They have made 7 open-market trades across 1 company since 2021, most recently 2026-05-22.
CIK 0001895035
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
7 open-market purchases totalling $918K since 2021, never a sale. Across 7 scored buys the stock is up 14.3% at ninety days, and 10.8 points ahead of the S&P over the same stretch.
7 scored purchases · one row per filing · discretionary only
| Ticker | Shares | Value |
|---|---|---|
| IMMX | 899,250 | $7.2M |
Shares reported on the most recent Form 4, priced at the 2026-05-29 close.
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 71% | 71% | 29% |
| Avg Move | +15.6% | +13.8% | +14.3% |
| Alpha | +16.9% | +13.8% | +10.8% |
| Scored | 7 | 7 | 7 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| IMMX | BUY | 2024-12-20 | 2024-12-26 | $2.19 | $104K | +1.8% | -13.0% | -17.2% |
| IMMX | BUY | 2024-08-21 | 2024-08-26 | $2.24 | $52K | -10.5% | -25.0% | -21.8% |
| IMMX | BUY | 2024-07-18 | 2024-07-31 | $2.12 | $20K | -12.3% | +1.4% | -19.0% |
| IMMX | BUY | 2023-12-08 | 2023-12-12 | $4.76 | $267K | +56.6% | +34.6% | -32.9% |
| IMMX | BUY | 2023-09-11 | 2023-09-18 | $2.78 | $200K | +43.2% | +12.1% | +157.6% |
| IMMX | BUY | 2023-09-08 | 2023-09-12 | $2.53 | $25K | +23.8% | +17.3% | +66.8% |
| IMMX | BUY | 2021-12-20 | 2021-12-20 | $5.00 | $250K | +6.3% | +69.0% | -33.7% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.